Back to Search
JAMES MANZANO, PHARMD
PHARMD
Pharmacist
NPI: 1124374566Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
PMID 19195847·Eur Psychiatry·2009
4-observational
Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer.
PMID 19139129·Mol Cancer Ther·2009
8-other
A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines.
PMID 19372549·Mol Cancer Ther·2009
8-other
Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma.
PMID 19186051·Eur J Cancer·2009
3-trial
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
PMID 19296535·Int J Cancer·2009
8-other
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
PMID 18335219·Cancer Chemother Pharmacol·2008
3-trial
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
PMID 18448328·Eur J Cancer·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1100 9TH AVE, MS C3-PO
SEATTLE, WA 98101 - Phone
- (206) 223-6877
Quick Facts
- NPI
- 1124374566
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile